Beijing Surgerii Technology Co., Ltd., found by Professor Xu Kai of Shanghai Jiaotong University, is a high-tech start-up company of surgical robots with independent core intellectual property rights. After returning from Columbia University, Professor Xu Kai proposed the novel “dual continuum mechanism” design through independent research and development at Shanghai Jiaotong University. By doing so, he overcame the continuum mechanism technology’s initial reliability and performance barriers. As a result, the fundamental prototype of the Surgerii’s single hole endoscopic surgery robot was created, boasting the smallest abdominal incision and the highest overall performance ever achieved. Beijing Surgerii has added the core technology of “dual continuum organization” under its command and received the invention patent of both China and the United States thanks to the implementation of Shanghai Jiaotong University’s policy of “independent transformation of scientific and technological achievements”. This has led to the development of several important technologies and fundamental elements, which have now reached the industrialization stage.

Since its establishment in 2001, Jiangsu Apon Medical Technology Co., Ltd. (hereinafter referred to as “Apon Medical”, stock code: 300753) has been actively engaged in the comfortable medical industry. To become the leader of comfortable medical intelligent devices in the medical sector, Apon has always started with clinical demands, relied on evidence-based medicine as the foundation for research and development, and prioritized quality over anything else. At present, its subsidiaries include Aipu Scientific Instruments (Jiangsu) Co., Ltd., etc.

InterMed is a high-tech medical information technology enterprise focusing on the development and production of artificial intelligence pathological diagnosis systems. The company creates a highly automated new diagnosis mode through precision optical instruments, artificial intelligence, big data analysis, cloud computing and other technologies, promotes the digital and intelligent development of clinical medicine, and takes the development of diagnosis and treatment technology of domestic grass-roots hospitals as its mission.

Beijing Advanced Medical Technologies, Ltd. Inc. is a high-tech company formed by students return from abroad. The headquarter of the company is situated in the central business district in Zhongguancun Biomedical Park, which is the center of Zhongguancun Science and Technology Park. The registered capital of Beijing Advanced is 22 million yuan. With the use of 3D precision printing technology, Beijing Advanced is a global leader in the R&D, manufacture of completely absorbable coronary stents, and peripheral vascular stents. The firm has full autonomous intellectual property rights and the most advanced patent technology for 3D fast vascular stent manufacturing in the world. The laser cutting technology Abbott and other foreign companies have used is fundamentally different from this one. High speed, high yield, and outstanding mechanical properties are among its features. As a result, this technology has unmatched advantages over the conventional method of producing biodegradable stents by laser cutting. The commercialization of China’s 3D printing technology will be made possible by the development of this highly revolutionary stent manufacturing technique. It will result in fundamental modifications to the production and application of cardiovascular stents. A competent, creative, and international talent team at Beijing Advanced is made up of specialists, professors, doctors, and masters. Beijing Advanced currently collaborates closely on scientific research with numerous prestigious universities and research institutions both domestically and internationally. Strong technical innovation and product development skills are possessed by Beijing Advanced. It has taken on the Ministry of Science and Technology’s 13th Five Year Support Plan, the Beijing Science and Technology Commission’s Strategic Emerging Industry Cultivation Project, and the Haidian Park of Zhongguancun Administrative Committee’s Small and Medium Sized Enterprise Innovation Project. Beijing Advanced will continue to broaden its application areas based on its core 3D precise printing technology, focus on creating high-quality intravascular implants and interventional solutions, and grow Beijing Advanced into a world-class medical device firm.

Hangzhou Huamai Medical Devices Co., Ltd. is a high-tech medical device and biotechnology company specializing in providing solutions for the repair of human musculoskeletal tissue defects. The company’s main goal is to create a cutting-edge biomaterial platform for application in the field of contemporary restorative medicine that will enable the natural regeneration and restoration of human injured musculoskeletal tissues (bone, cartilage, tendon, etc.). To better serve the hundreds of millions of patients who require bone grafts around the world, the company will introduce the first batch of bone regeneration medical materials for orthopedic surgery, focusing primarily on small area bone defect filling and regeneration, large area bone defect repair and reconstruction, spinal fusion surgery, alveolar bone regeneration in dental surgery, etc.

Resproly is a large company that focuses on the R&D, manufacturing, and marketing of respiratory system devices and inhalation and delivery formula technologies. The business has four main inhalation preparation R&D and production platforms, including nasal spray, dry powder inhalers, nebulizers, and quantitative inhalation aerosol (MDI). The product line being studied includes a broad variety of respiratory system treatments for treating conditions like Parkinson’s disease, diabetes, chronic obstructive pulmonary disease (COPD), and asthma, among others with significant clinical requirements. The company’s goal is to dominate this industry's medicine development, manufacture, and research.